Supplementary Materials

FIGURES




Figure S1: No difference of CD4⁺ and CD8⁺ cells among CD3⁺ T cells in MS patients and healthy controls. Shown are CD3⁺ T cell gating strategy (**A**) and scatter plots (**B**; mean and 95% CI) of CD4⁺ and CD8⁺ cells among CD3⁺ T cells in untreated MS ("MS") patients and healthy controls ("HC"). Comparisons between MS and HC were made using one-sided t-test; n.s.=not significant.




Figure S2: Rituximab depletes CD3⁺**CD20**^{dim} **T cells.** Shown are representative flow cytometry plots of CD3⁺CD20^{dim} T cells in an untreated MS patient (UNT) and in patients at the indicated time points after RTX treatment.




Figure S3: Flow cytometry of B cell subsets. Shown are representative flow cytometry plots demonstrating the gating strategy to identify the indicated B cell subpopulations: Naïve B cells (**N**, CD19+CD24loCD38loCD27-IgD+), transitional B cells (**Tr**, CD19+CD24hiCD38hiCD27-IgD+), unswitched memory B cells (**USM**, CD19+CD27+IgD+), double negative B cells (**DN**, CD19+CD27-IgD-), switched memory B cells (**SM**, CD19+ CD27+IgD-), and plasma cells/plasmablasts (**PC**, CD19+ CD27hiCD38hiIgD-).